4/4 Lastly, a personal connection at #ESMO26 in #ProstateCancer. 🧬 #JNJ6143, formerly #HLD0915 — 2216O - Updated data for a novel treatment mechanism with an oral AR-targeted #RIPTAC in mAPMR (mCRPC), including patients with high-risk molecular features. - Looking forward to presentation by @BGarmezy with data on durable activity and tolerability at the selected dose in ARPI-resistant, heavily pretreated disease. Glad to contribute to this phase I/II work as a co-author and site PI at Duke. @DukeCancer @OncHahn @AarmstrongDuke @myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow @DukeGUCancer